DoW Tuberous Sclerosis Complex, Clinical Translational Research Award
This grant funds collaborative research to advance preclinical or clinical findings toward new diagnosis, prognosis, or treatment options for tuberous sclerosis complex.
Funder: Dept. of the Army -- USAMRAA
Due Dates: July 23, 2026: Pre-Application (Letter of Intent) | August 6, 2026: Full Application | August 13, 2026: End of Application Verification Period
Funding Amounts: Total program funding: $3.5M; up to $1.6M (single PI) or $1.9M (partnering PIs) over 3 years; ~2 awards expected.
Summary: Supports clinical translational research to advance diagnosis, prognosis, or treatment of tuberous sclerosis complex (TSC) toward clinical application.
Key Information: Multiple PIs allowed; pre-application required; clinical trials are permitted.
Description
This opportunity supports research that moves promising preclinical and/or clinical findings closer to real-world clinical application for tuberous sclerosis complex (TSC). The focus is on studies with clear translational potential, such as pilot clinical trials, biomarker validation, studies analyzing human data or clinical samples, and research to improve clinical care or develop new guidelines for TSC. Projects must include a clinical component (purely animal studies are not eligible).
Distinctive features of this mechanism include the option for multiple Principal Investigators (PIs) on a single project. The program encourages collaborative, multidisciplinary efforts, including partnerships between academia, industry, and federal agencies. Both preclinical and clinical studies are eligible, provided they are designed to meaningfully advance patient care.
